Abstract
Two applications claim 1-acyl-4-benzyl-2,5-dimethylpiperazine derivatives as CCR1 antagonists useful in the treatment of inflammatory diseases. The two applications respectively claim compounds in which the acyl groups are 2-heteroaryl or cinnamoyl (and certain heterocyclic analogues thereof). Both applications describe compounds with good receptor affinity and good in vivo pharmacokinetic properties, displaying a superior profile relative to closely related prior art compounds.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
